With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.344329-76-6,Tetrahydro-2H-pyran-4-carboxamide,as a common compound, the synthetic route is as follows.
Example 51 A suspension of Example B5 (0.596 g, 4.61 mmol) in dioxane (15 mL) was treated with oxalyl chloride (0.820 mL, 9.69 mmol), stirred at RT for 10 min, then heated at 80¡ã C. for 4 h. The mixture was concentrated to dryness, treated with Example A9 (0.200 g, 0.732 mmol), pyridine (0.125 mL, 1.481 mmol) and THF (5 mL) and stirred at RT overnight. The mixture was concentrated to dryness and purified via reverse-phase chromatography (MeCN/H2O with 0.1percent TFA). The organics were removed under reduced pressure and the aqueous residue was treated with satd. NaHCO3, extracted with EtOAc (4*) and the combined organics were dried over Na2SO4 and concentrated to dryness to afford N-((5-((2-(3,3-dimethylureido)pyridin-4-yl)oxy)pyridin-2-yl)carbamoyl)tetrahydro-2H-pyran-4-carboxamide (45 mg, 14percent). 1H NMR (400 MHz, DMSO-d6): delta 11.05 (s, 1H), 10.88 (br s, 1H), 8.91 (s, 1H), 8.23 (d, J=2.9 Hz, 1H), 8.11 (d, J=5.7 Hz, 1H), 8.07 (d, J=9.0 Hz, 1H), 7.71 (dd, J=9.0, 2.9 Hz, 1H), 7.38 (d, J=2.4 Hz, 1H), 6.60 (dd, J=5.7, 2.4 Hz, 1H), 3.90-3.85 (m, 2H), 3.30-3.25 (m, 2H), 2.87 (s, 6H), 2.69-2.64 (m, 1H), 1.74-1.68 (m, 2H), 1.66-1.55 (m, 2H); MS (ESI) m/z: 429.2 (M+H+).
344329-76-6, The synthetic route of 344329-76-6 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Deciphera Pharmaceuticals, LLC; Flynn, Daniel L.; Caldwell, Timothy Malcolm; Samarakoon, Thiwanka; Vogeti, Lakshminarayana; Kaufman, Michael D.; Patt, William C.; Ahn, YuMi; US2014/275016; (2014); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics